Skip to content

Deprescribing of Diabetes Regimens in Long Term Care Residents With Alzheimer's

Deprescribing of Diabetes Treatment Regimens in Long Term Care (LTC) Residents With Alzheimer's Disease or Related Dementias (ADRD)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05535478
Enrollment
130
Registered
2022-09-10
Start date
2023-01-31
Completion date
2025-07-14
Last updated
2025-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia, Diabetes, Hypoglycemia; Drug

Keywords

older adults, long term care facility, high risk medications, hypoglycemia, deprescribing, diabetes, dementia

Brief summary

Objectives To 1) examine the ability of the STRIDE (Simplification of Treatment Regimens and Individualized Diabetes Education) educational program to increase deprescribing of high hypoglycemia risk glucose-lowering medications (HRMs) among long term care facility (LTCF) residents with ADRD, 2) assess key implementation constructs (secondary outcomes) of the STRIDE program, including acceptability, appropriateness, and feasibility, and 3) validate the primary HRM use outcome measure.

Interventions

BEHAVIORALSTRIDE

a. Targeted providers for STRIDE program: i. Clinical staff at the LTCF who participate in deprescribing at the facilities (physicians (MDs), physician's assistants (PAs), nurse practitioners (NPs), clinical pharmacists): clinical staff members caring for LTCF residents with ADRD and diabetes at 6 LTCFs in the Ohio and Michigan areas will be invited via email from the LTCF leadership to participate in the STRIDE education program. The STRIDE program consist of practical algorithms and educational material, which they are free to view at any time, and participation in 2 webinars and monthly telementoring calls

Sponsors

Brown University
CollaboratorOTHER
Theoria Medical
CollaboratorUNKNOWN
Joslin Diabetes Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Clinical staff at the LTCF (MDs, PAs, NPs, clinical pharmacists) - (Targeted providers for STRIDE program) * Clinical staff that participated in the STRIDE program (Providers doing stakeholder exit interviews)

Exclusion criteria

* Consistent with the pragmatic nature of the trial, there are no

Design outcomes

Primary

MeasureTime frameDescription
Change in proportion of long term care facility (LTCF) residents with Alzheimer's disease adn related dementias (ADRD) and diabetes with high risk medications (HRM) useBaseline vs 6 monthsHRM use will include any sulfonylurea use (i.e., glyburide, glipizide, glimepiride, or chlorpropamide) and any insulin use.

Secondary

MeasureTime frameDescription
Acceptability of the STRIDE Educational Program6 monthsThe extent to which the program is agreeable to LTCF staff- using the Acceptability of Intervention Measure (AIM)
Appropriateness of the STRIDE Educational Program6 monthsThe extent to which the program is suitable for a particular purpose, i.e., to improve the frequency at which LTCF staff attempt diabetes medication regimen deprescribing- using the Intervention Appropriateness Measure (IAM)
Feasibility of the STRIDE Educational Program6 monthsThe extent to which the program is practical at the LTCF level- using the Feasibility of Intervention Measure (FIM)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026